PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers.

9060Background: HER2 mutations are present in 3% of lung cancers. Response to immune checkpoint blockade (ICB) in this subset of lung cancers is unknown. We evaluate the landscape of PD-L1 and tumo...